U.S. markets close in 45 minutes

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5750+0.0350 (+2.27%)
As of 03:15PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close1.5400
Bid1.5600 x 1200
Ask1.5700 x 1200
Day's Range1.5000 - 1.5900
52 Week Range0.6400 - 4.2400
Avg. Volume6,581,545
Market Cap272.217M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-0.4970
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.64
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RIGL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Rigel Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Benzinga

    Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact

    Rigel Pharmaceuticals Inc (NASDAQ: RIGL) and Forma Therapeutics Inc (NASDAQ: FMTX) entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib. Olutasidenib is an oral, small molecule inhibitor of mIDH1 being investigated for relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. The FDA has accepted Forma's marketing application for olutasidenib with the Prescription Drug User Fee Act target date of February 15, 2023. Relat

  • Zacks

    Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

    Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.